305 related articles for article (PubMed ID: 26104047)
1. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.
Lobatón T; Ferrante M; Rutgeerts P; Ballet V; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2015 Aug; 42(4):441-51. PubMed ID: 26104047
[TBL] [Abstract][Full Text] [Related]
2. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
3. The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.
Khan N; Trivedi C; Shah Y; Patel D; Lewis J; Yang YX
Inflamm Bowel Dis; 2018 May; 24(6):1274-1279. PubMed ID: 29522099
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
[TBL] [Abstract][Full Text] [Related]
6. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
[TBL] [Abstract][Full Text] [Related]
7. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy.
Zabana Y; Domènech E; San Román AL; Beltrán B; Cabriada JL; Saro C; Araméndiz R; Ginard D; Hinojosa J; Gisbert JP; Mañosa M; Cabré E; Gassull MA
Inflamm Bowel Dis; 2008 Oct; 14(10):1387-91. PubMed ID: 18452206
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events.
Asscher VER; van der Vliet Q; van der Aalst K; van der Aalst A; Brand EC; van der Meulen-de Jong AE; Oldenburg B; Pierik MJ; van Tuyl B; Mahmmod N; Maljaars PWJ; Fidder HH;
Int J Colorectal Dis; 2020 Dec; 35(12):2331-2338. PubMed ID: 32860081
[TBL] [Abstract][Full Text] [Related]
9. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
Bröms G; Granath F; Stephansson O; Kieler H
Scand J Gastroenterol; 2016 Dec; 51(12):1462-1469. PubMed ID: 27739352
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
11. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
13. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
14. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
[TBL] [Abstract][Full Text] [Related]
15. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
[TBL] [Abstract][Full Text] [Related]
16. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Khan N; Vallarino C; Lissoos T; Darr U; Luo M
Drugs Aging; 2017 Nov; 34(11):859-868. PubMed ID: 29170864
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma.
Nissen LHC; Pierik M; Derikx LAAP; de Jong E; Kievit W; van den Heuvel TRA; van Rosendael AR; Plasmeijer EI; Dewint P; Verhoeven RHA; Overbeek LIH; Nagtegaal ID; Hoentjen F; van der Meulen-de Jong AE
Inflamm Bowel Dis; 2017 Nov; 23(11):2018-2026. PubMed ID: 28837522
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
19. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.
Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
Aliment Pharmacol Ther; 2017 Mar; 45(5):653-659. PubMed ID: 28074487
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
